Altimmune, Inc. (ALT) Investor Relations Documents

Altimmune, Inc. (ALT) investor relations documents from the company's IR site: 2 presentations, 38 press releases; latest deck 2026-08-11. Read in-app with summaries. First-party data.

Corporate Presentation August 2026: Altimmune's Pemvidutide, a dual GLP-1/glucagon agonist, shows promise in Phase 2 trials for MASH, AUD, and ALD, with Phase 3 MASH trials underway and significant cash reserves.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-12Press releasePress release
2026-08-12Press releaseAltimmune Announces Second Quarter 2026 Financial Results and Business Update
2026-08-11PresentationCorporate Presentation August 2026
2026-08-05Press releasePress release
2026-08-05Press releaseAltimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
2026-08-03Press releasePress release
2026-08-03Press releaseAltimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
2026-07-28Earnings deckRECLAIM Phase 2 Trial in AUD Topline Results Presentation
2026-07-28Press releasePress release
2026-07-28Press releaseAltimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
2026-05-28Press releasePress release
2026-05-28Press releasePemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Pr
2026-05-27Press releasePress release
2026-05-27Press releasePress release
2026-05-27Press releaseNew IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured F
2026-05-27Press releaseAltimmune to Participate in Upcoming Investor Conferences
2026-05-13Press releasePress release
2026-05-13Press releasePress release
2026-05-13Press releaseAltimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Co
2026-05-13Press releaseAltimmune Announces First Quarter 2026 Financial Results and Business Update
2026-05-06Press releasePress release
2026-05-06Press releaseAltimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
2026-04-27Press releasePress release
2026-04-27Press releaseAltimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
2026-04-22Press releasePress release
2026-04-22Press releasePress release
2026-04-22Press releaseAltimmune Announces Proposed Underwritten Public Offering of Securities
2026-04-22Press releaseAltimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
2026-03-05Press releasePress release
2026-03-05Press releaseAltimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
2026-03-02Press releasePress release
2026-03-02Press releaseAltimmune to Participate in Upcoming Investor Conferences
2026-02-26Press releasePress release
2026-02-26Press releaseAltimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
2026-01-29Press releasePress release
2026-01-29Press releaseAltimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
2026-01-27Press releasePress release
2026-01-27Press releaseAltimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
2026-01-05Press releasePress release
2026-01-05Press releaseAltimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

ALT overview · ALT earnings · ALT financials · ALT KPIs · ALT ownership · ALT peers · ALT filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.